Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in conjunction with a directed new issue of shares
Mandate

Vinge advises Smart Eye in conjunction with a directed new issue of shares

October 06, 2020 Capital Markets and Public M&A

Vinge has advised Smart Eye AB in connection with a directed new issue of 1 511 898 new shares at a subscription price of SEK 125 per share, which means that Smart Eye will acquire MSEK 189 prior to issue costs.

The subscription price has been determined through an accelerated book building procedure and corresponds to a discount of 2.9 per cent compared with the volume‑weighted average price on Nasdaq First North Growth Market on 5 October 2020.

Vinge’s team consisted of Anders Strid, Edin Agic and Jacob Benzow.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025